Recent advances in anti-tumour necrosis factor (TNF) therapy in rheumatoid arthritis. Focus on the soluble TNF receptor p75 fusion protein, etanercept

BioDrugs

Volumn 11, Issue 3, 1999, Pages 201-210

  Moreland, Larry W ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Division of Clinical Immunology and Rheumatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HYBRID PROTEIN; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR P75 FUSION PROTEIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE PRODUCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; ERYTHEMA; HUMAN; INFLAMMATION; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; JOINT DESTRUCTION; MORNING STIFFNESS; MULTICENTER STUDY; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033016199     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911030-00006     Document Type: Review

References (80)

1. 1. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4: 754-9
2. 2. Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125-32
3. 3. Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041-5
4. 4. Ahmadzadeb N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-alpha on superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990; 8: 387-91
5. 5. MacNaul KL, Chartrain N, Lark M, et al. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and then natural inhibitor, TIMP, in rheumatoid synovial fibroblasts. Matrix 1992; 1 Suppl.: 198-9
6. 6. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immuol 1993; 94: 145-9
7. 7. Moser RB, Schleiffenbaum B, Groscurth P, et al. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989; 83: 444-55
8. 8. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effects of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 11: 244-7
9. 9. Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis-alpha. Eur J Immunol 1991; 21: 2575-9
10. 10. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73: 431-45
11. 11. Seckinger P, Zhang J, Hauptmann B, et al. Characterization of a tumor necrosis factor a (TNF) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990; 87: 5188-92
12. 12. Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Them 1989; 264: 11974-80
13. 13. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42: 270-5
14. 14. Deleuran BW, Chu CQ, Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992; 35: 1170-8
15. 15. Pennica D, Lam VT, Mize NK, et al. Biochemical properties of the 75Kda tumor necrosis factor receptor: characterization of the ligand binding, internalization, and receptor phosphorylation. J Biol Chem 1992; 267: 21172-8
16. 16. Westacott CI, Atkins RM, Dieppe PA, et al. Tumor necrosis factor-α receptor expression on chondrocytes isolated from human articular cartilage. J Rhematol 1994; 21: 1710-5
17. 17. Barrera P, Boerbooms AM, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070-9
18. 18. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-9
19. 19. Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485-9
20. 20. Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111-20
21. 21. Heilig B, Fiehn C, Brockhaus M, et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993; 13: 321-8
22. 22. Andus T, Gross V, Holstege A, et al. High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatology 1992; 16: 749-55
23. 23. Austgulen R, Liabakk NB, Lien E, et al. Increased levels of soluble tumor necrosis factor-alpha receptors in scrum from pregnant women and in serum and urine samples from newborns. Pediatr Res 1993; 33: 82-7
24. 24. Baumann P, Romero R, Berry S, et al. Evidence of participation of the soluble tumor necrosis factor receptor 1 in the host response to intrauterine infection in preterm labor. Am J Reprod Immunol 1993; 30: 184-93
25. 25. Bemelmans MHA, Greve JWM, Gouma DJ, et al. Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality. Gut 1996; 38: 447-53
26. 26. Brockhaus M, Bar-Khayim Y, Gurwicz S, et al. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992; 42: 663-7
27. 27. Créange A, Bélec L, Clair B, et al. Circulating rumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barré syndrome. J Neurol 1996; 68: 95-9
28. 28. Digel W, Porzsolt F, Schmid M, et al. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992; 89: 1690-3
29. 29. Elsasser-Beile U, Callati H, Weber W, et al. Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients. Tumor Biol 1994; 15: 17-24
30. 30. Engel A, Kern P, Kern WV. Levels of cytokines and cytokine inhibitors in the neutropenic patients with α-hemolytic streptococcus shock syndrome. Clin Infect Dis 1996, 23: 785-9
31. 31. Froon AH, Bemelmans MH, Greve JW, et al. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 1994; 22: 803-9
32. 32. Furukawa S, Masubara T, Umezawa Y, et al. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. Pediatrics 1994; 124: 721-5
33. 33. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlated with disease activity. J Rheumatol 1997; 24: 303-8
34. 34. Girardin E, Roux-Lombard P, Grau GE, et al. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 1992; 76: 20-3
35. 35. Hino T, Nakamura H, Shibata Y, et al. Elevated levels of type 11 soluble tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis. Lung 1997; 175: 187-93
36. 36. Ichiyama T, Hayashi T, Nishikawa M, et al. Cerebrospinal fluid levels of soluble tumour necrosis factor receptor in acute encephalitis. J Neurol 1996; 243: 457-60
37. 37. Kobayashi H, Fukata J, Murakami N, et al. Tumor necrosis factor receptors in the pituitary cells. Brain Res 1997; 758: 45-50
38. 38. Kraus T, Mehrabi A, Arnold J, et al. Evaluation of soluble tumor necrosis factor receptors with orthotopic liver transplantation. Transplant Proc 1992; 24: 2539-41
39. 39. Kupfermine MJ, Peaceman AM, Aderka D, et al. Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe preeclampsia. Obstet Gynecol 1996; 88: 420-7
40. 40. Lucas R, Lou J, Morel DR, et al. TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukoc Biol 1997; 61: 551-8
41. 41. Messer J, Eyer D, Donato L, et al. Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. J Pediatr 1996; 129: 574-80
42. 42. Rizzardi GP, Barcellini W, Tambussi G, et al. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-α and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996; 10: F45-50
43. 43. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992; 90: 533-6
44. 44. Tsukada N, Matsuda M, Miyagi K, et al. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993; 43: 2679-82
45. 45. Ward RA, Gordan L. Soluble tumor necrosis factor receptors are increased in hemodialysis patients. ASAIO J 1993; 39: M782-M6
46. 46. Warzacha K, Salles G, Bienvenu J, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 1997; 15: 499-508
47. 47. Yoshida S, Hashimoto S, Nakayama T, et al. Elevation of serum soluble tumour necrosis factor (TNF) receptor and IL-1 receptor antagonist levels in bronchial asthma. Clin Exp Immunol 1996; 106: 73-8
48. 48. Zangerle R, Gallati H, Sarcletti M, et al. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J AIDS 1994; 7: 79-85
49. 49. Pennica D, Lam VT, Mize NK, et al. Biochemical properties of the 75-kDa tumor necrosis factor receptor: characterization of ligand binding, internalization, and receptor phosphorylation. J Biochem 1992; 267: 21172-8
50. 50. Tartaglia LA, Weber RF, Figari IS, et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci USA 1991; 88: 9292-6
51. 51. Moreland LW, Heck LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40: 393-409
52. 52. Ferrante A, Hauptmann B, Seckinger P, et al. Inhibition of tumour necrosis factor alpha (TNF-α)-induced neutrophil respiratory burst by a TNF inhibitor. Immunology 1991; 72: 440-2
53. 53. Tilg H, Shapiro L, Atkins MB, et al. Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol 1993; 151: 3299-307
54. 54. Cope AP, Gibbons DL, Aderke D, et al. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of p55 and p75 TNF-R on synovial joint mononuclear cells. Cytokine 1993; 5: 205-12
55. 55. Taylor DJ. Cytokine combinations increase p75 tumor necrosis factor receptor binding and stimulate receptor shedding in rheumatoid synovial fibroblasts. Arthritis Rheum 1994; 37: 232-5
56. 56. Gatanaga T, Hwang CD, Kohr W, et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990; 87: 8781-4
57. 57. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31
58. 58. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Nat Acad Sci 1992; 89: 9784-8
59. 59. Williams RO, Mason LJ, Feldmann M, et al. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Nat Acad Sci USA 1994; 91: 2762-6
60. 60. Williams RO, Chrayeb J, Feldman M, et al. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD-4. Immunology 1995; 84: 433-9
61. 61. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 11: 6602-7
62. 62. Piguet PF, Grau GE, Vesin C, et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510-4
63. 63. Joosten LAB, Helsen MMA, van de Loo FAJ, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797-809
64. 64. van de Loo FA, Joosten LA, van Lent PL, et al. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen-and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164-72
65. 65. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α. Arthritis Rheum 1993; 36: 1681-90
66. 66. Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
67. 67. Kavanaugh AF, Cush JJ, St Clair EW, et al. Anti-TNF monoclonal antibody (Mab) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX); results of a double-blind, placebo controlled multicenter trial (abstract). Arthritis Rheum 1996; 39: S123
68. 68. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 41: 1552-63
69. 69. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42
70. 70. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor TNF receptors arc effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF Carriers and TNF antagonists. J Immunol 1993; 151: 1548-61
71. 71. Nam MH, Reda D, Boujouko S, et al. Recombinant human chimeric tumor necrosis factor (TNF) receptor (TNFR: Fc): Safety and pharmacokinetics in humans (abstract). Clin Res 1993; 41
72. 72. Moreland LW, Margolies GR, Heck LW, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1849-55
73. 73. Hochberg MC, Chang RW, Dwosh I, et al. American College of Rheumatology, 1991, revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498-502
74. 74. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Eng J Med 1997; 337: 141-7
75. 75. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomised controlled trial. Ann Intern Med. In press
76. c fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9
77. 77. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40
78. 78. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant huan tumour necrosis factor receptor (p75)-c fusion protein. N Engl J Med 1997; 337: 141-7
79. 79. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Tranplantation 1996; 61: 224-8
80. 80. Beutler B, van Huffel C. Unravelling function in theTNF ligand and receptor families. Science 1994; 264: 667-8